Cefotaxime + Sulbactam

Generic Medicine Info
Indications and Dosage
Genitourinary infections, Lower respiratory tract infections
Adult: Mild to moderate infections: 1/0.5 g to 2/1 g of cefotaxime/sulbactam every 8-12 hrs. Moderate to severe infections: 1/0.5 g to 2/1 g of cefotaxime/sulbactam every 6-8 hrs. Max (sulbactam): 4 g.
Child: 100/50 mg to 150/75 mg of cefotaxime/sulbactam /kg/day in 3 divided doses. Life-threatening infections: Dose of cefotaxime may be increased up to 12 g/day.
Renal Impairment
Dose adjustment may be needed.
Hypersensitivity to cefotaxime, sulbactam or the combination.
Special Precautions
Previous hypersensitivity to penicillins or other drugs; patients with renal insufficiency; history of GI disease, esp colitis. Pregnancy and lactation.
Adverse Reactions
Local reactions including pain at the Inj site and phloebitis. Others: Skin rash, diarrhoea, nausea, vomiting and colitis.
Drug Interactions
Concomitant admin of cephalosporins and aminoglycoside antibiotics.
Description: Cefotaxime is a bactericidal drug, which inhibits the bacterial wall synthesis of the actively dividing cells by binding to one or more penicillin-binding proteins. Sulbactam is a semisynthetic β-lactam sulphone, which inhibits β-lactamases of the Richmond types II, III, IV and V (plasmid or chromosomally mediated). This inhibition is reported to be both reversible and irreversible. It acts as a suicide inhibitor by forming a reversible inactive enzyme-sulbactam complex. This reversible acyl-intermediate may then revert to a more stable complex, which irreversibly inhibits the β-lactamase. Sulbactam is able to protect the activity of various β-lactam antibiotics by rendering β-lactamases inactive.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefotaxime + Sulbactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in